SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001564590-20-019689
Filing Date
2020-04-29
Accepted
2020-04-29 16:02:26
Documents
64
Period of Report
2020-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q apls-10q_20200331.htm   iXBRL 10-Q 2242417
2 EX-31.1 apls-ex311_9.htm EX-31.1 18437
3 EX-31.2 apls-ex312_7.htm EX-31.2 17553
4 EX-32.1 apls-ex321_8.htm EX-32.1 8565
5 EX-32.2 apls-ex322_10.htm EX-32.2 8576
  Complete submission text file 0001564590-20-019689.txt   6993736

Data Files

Seq Description Document Type Size
6 XBRL TAXONOMY EXTENSION SCHEMA apls-20200331.xsd EX-101.SCH 48933
7 XBRL TAXONOMY EXTENSION CALCULATION LINKBASE apls-20200331_cal.xml EX-101.CAL 41755
8 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE apls-20200331_def.xml EX-101.DEF 148498
9 XBRL TAXONOMY EXTENSION LABEL LINKBASE apls-20200331_lab.xml EX-101.LAB 358211
10 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE apls-20200331_pre.xml EX-101.PRE 275788
25 EXTRACTED XBRL INSTANCE DOCUMENT apls-10q_20200331_htm.xml XML 1156596
Mailing Address 100 FIFTH AVENUE WALTHAM MA 02451
Business Address 100 FIFTH AVENUE WALTHAM MA 02451 617-977-5700
Apellis Pharmaceuticals, Inc. (Filer) CIK: 0001492422 (see all company filings)

IRS No.: 271537290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-38276 | Film No.: 20830158
SIC: 2834 Pharmaceutical Preparations
Office of Life Sciences